FDA warns against epilepsy drug valproate for pregnant women

The FDA, in a warning issued Thursday, said that women who took valproate products for epilepsy and psychiatric problems during pregnancy increased the risk that their babies would have developmental delays, compared with women who took other anti-seizure drugs. Medical providers should "weigh the benefits and risks of valproate when prescribing this drug to women of childbearing age, particularly when treating a condition not usually associated with permanent injury or death," the FDA said. "Alternative medications that have a lower risk of adverse birth outcomes should be considered."

Share

This news summary appeared in AAP SmartBrief on 07/01/2011
Click here to view the full issue.


View the original article:
Los Angeles Times

Want to see more news summaries?
Sign up for AAP SmartBrief

AAP SmartBrief is a FREE, daily email newsletter that summarizes the day's top industry news from hundreds of sources. Each day, subscribers receive 8-10 headlines and news summaries like the one to the left
Sign up:
About SmartBrief
SmartBrief is the leading online publisher of targeted business news and information by industry. By combining technology and editorial expertise, SmartBrief filters thousands of sources daily to deliver the most relevant industry news in partnership with more than 180 trade associations, professional societies nonprofits and corporate entities